Back to News
Market Impact: 0.28
MAIA Reaches Enrollment Milestone Of 65 In Phase 3 THIO-104 For Ateganosine In Lung Cancer
Source: Nasdaq
Healthcare & Biotech
MAIA Biotechnology reached its target enrollment of 65 patients in the Phase 3 THIO-104 trial evaluating Ateganosine as a third-line treatment for advanced non-small cell lung cancer. Completion of enrollment is a positive clinical-development milestone, but efficacy and safety results remain the key valuation catalysts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MAIA0.65
More News
- Heidi CEO on AI in Healthcare, $900M valuation
- Guggenheim Names Top Stock Pick in Biotech Sector
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
- US and Iran Sit Down for Talks at the UN: Evening Briefing Americas
- In Senegal, a mother’s ordeal exposes a health system under strain
- Halozyme Therapeutics completes $1.5 billion convertible notes offering
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI